Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Ottawa Hospital · University of Ottawa · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
641
total citations
- FWCI
- 69.92
- Percentile
- 100%
- References
- 31
Citations per year
Authors
20- GGGlenwood GossCorresponding
Ottawa Hospital, University of Ottawa
- CTChun‐Ming Tsai
Taipei Veterans General Hospital, National Yang Ming Chiao Tung University
- FAFrances A. Shepherd
Princess Margaret Cancer Centre
- LBLyudmila Bazhenova
Moores Cancer Center, University of California San Diego
- JSJong Seok Lee
Seoul National University Bundang Hospital
Topics & keywords
Topics
Keywords
- Osimertinib
- Lung cancer
- Medicine
- Open label
- Cancer
- Oncology
- Internal medicine
- Adenocarcinoma
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.